Filing Details

Accession Number:
0001387131-18-006131
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-11-13 20:01:31
Reporting Period:
2018-11-08
Accepted Time:
2018-11-13 20:01:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
25743 Therapeuticsmd Inc. TXMD Pharmaceutical Preparations (2834) 870233535
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1532233 Brian Bernick 6800 Broken Sound Pkwy Nw, Third Floor
Boca Raton FL 33487
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-11-08 91,400 $0.10 6,648,771 No 4 M Indirect By BF Investment Enterprises, Ltd.
Common Stock Disposition 2018-11-08 91,400 $4.93 6,557,371 No 4 S Indirect By BF Investment Enterprises, Ltd.
Common Stock Acquisiton 2018-11-09 91,400 $0.10 6,648,771 No 4 M Indirect By BF Investment Enterprises, Ltd.
Common Stock Disposition 2018-11-09 91,400 $4.83 6,557,371 No 4 S Indirect By BF Investment Enterprises, Ltd.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Indirect By BF Investment Enterprises, Ltd.
No 4 S Indirect By BF Investment Enterprises, Ltd.
No 4 M Indirect By BF Investment Enterprises, Ltd.
No 4 S Indirect By BF Investment Enterprises, Ltd.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2018-11-08 91,400 $0.00 91,400 $0.10
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2018-11-09 91,400 $0.00 91,400 $0.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
640,310 2012-01-01 2019-01-01 No 4 M Indirect
548,100 2012-01-01 2019-01-01 No 4 M Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 242,000 Direct
Common Stock 3,000 Indirect By BF Management, LLC
Footnotes
  1. The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
  2. The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.6 to $5.05, inclusive. The Reporting Person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.925, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The reported securities are held by the GP. As disclosed in footnote 1 above, the Reporting Person, together with his spouse as tenants by the entirety, holds a 70.6% membership interest in the GP. The Reporting Person disclaims beneficial ownership of the reported securities held by the GP, except to the extent of his pecuniary interest therein.